These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 14993929)

  • 1. A functional genomic study on NCI's anticancer drug screen.
    Li KC; Yuan S
    Pharmacogenomics J; 2004; 4(2):127-35. PubMed ID: 14993929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Linking the growth inhibition response from the National Cancer Institute's anticancer screen to gene expression levels and other molecular target data.
    Wallqvist A; Rabow AA; Shoemaker RH; Sausville EA; Covell DG
    Bioinformatics; 2003 Nov; 19(17):2212-24. PubMed ID: 14630650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of in vitro and in vivo activities in the National Cancer Institute's anticancer screen with respect to chemical structure, target specificity, and mechanism of action.
    Huang R; Wallqvist A; Covell DG
    J Med Chem; 2006 Mar; 49(6):1964-79. PubMed ID: 16539384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NCI's anticancer drug screening program may not be selecting for clinically active compounds.
    Brown JM
    Oncol Res; 1997; 9(5):213-5. PubMed ID: 9306428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Data mining of NCI's anticancer screening database reveals mitochondrial complex I inhibitors cytotoxic to leukemia cell lines.
    Glover CJ; Rabow AA; Isgor YG; Shoemaker RH; Covell DG
    Biochem Pharmacol; 2007 Feb; 73(3):331-40. PubMed ID: 17109823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Web-based tools for mining the NCI databases for anticancer drug discovery.
    Fang X; Shao L; Zhang H; Wang S
    J Chem Inf Comput Sci; 2004; 44(1):249-57. PubMed ID: 14741034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methyl protogracillin (NSC-698792): the spectrum of cytotoxicity against 60 human cancer cell lines in the National Cancer Institute's anticancer drug screen panel.
    Hu K; Yao X
    Anticancer Drugs; 2001 Jul; 12(6):541-7. PubMed ID: 11460001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticancer metal compounds in NCI's tumor-screening database: putative mode of action.
    Huang R; Wallqvist A; Covell DG
    Biochem Pharmacol; 2005 Apr; 69(7):1009-39. PubMed ID: 15763539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mining the National Cancer Institute's tumor-screening database: identification of compounds with similar cellular activities.
    Rabow AA; Shoemaker RH; Sausville EA; Covell DG
    J Med Chem; 2002 Feb; 45(4):818-40. PubMed ID: 11831894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive analysis of pathway or functionally related gene expression in the National Cancer Institute's anticancer screen.
    Huang R; Wallqvist A; Covell DG
    Genomics; 2006 Mar; 87(3):315-28. PubMed ID: 16386875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protodioscin (NSC-698 796): its spectrum of cytotoxicity against sixty human cancer cell lines in an anticancer drug screen panel.
    Hu K; Yao X
    Planta Med; 2002 Apr; 68(4):297-301. PubMed ID: 11988850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Polygenetic pharmacogenomic strategies to identify drug sensitivity biomarkers].
    Nishiyama M
    Gan To Kagaku Ryoho; 2005 Nov; 32(12):1902-7. PubMed ID: 16282724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Use of DNA Microarrays to Investigate the Pharmacogenomics of Drug Response in Living Systems.
    Villeneuve DJ; Parissenti AM
    Curr Top Med Chem; 2004; 4(13):1327-1343. PubMed ID: 15379648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linking pathway gene expressions to the growth inhibition response from the National Cancer Institute's anticancer screen and drug mechanism of action.
    Huang R; Wallqvist A; Thanki N; Covell DG
    Pharmacogenomics J; 2005; 5(6):381-99. PubMed ID: 16103895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PGAGENE: integrating quantitative gene-specific results from the NHLBI programs for genomic applications.
    Lee K; Kohane IS; Butte AJ
    Bioinformatics; 2003 Apr; 19(6):778-9. PubMed ID: 12691993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenomic analysis: correlating molecular substructure classes with microarray gene expression data.
    Blower PE; Yang C; Fligner MA; Verducci JS; Yu L; Richman S; Weinstein JN
    Pharmacogenomics J; 2002; 2(4):259-71. PubMed ID: 12196914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening drug effects in patient-derived cancer cells links organoid responses to genome alterations.
    Jabs J; Zickgraf FM; Park J; Wagner S; Jiang X; Jechow K; Kleinheinz K; Toprak UH; Schneider MA; Meister M; Spaich S; Sütterlin M; Schlesner M; Trumpp A; Sprick M; Eils R; Conrad C
    Mol Syst Biol; 2017 Nov; 13(11):955. PubMed ID: 29180611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NCI's cancer information systems--bringing medical knowledge to clinicians.
    Hubbard SM; Martin NB; Thurn AL
    Oncology (Williston Park); 1995 Apr; 9(4):302-6, 309 discussion 309, 313-4. PubMed ID: 7547196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic interrogation of mechanism(s) underlying cellular responses to toxicants.
    Amin RP; Hamadeh HK; Bushel PR; Bennett L; Afshari CA; Paules RS
    Toxicology; 2002 Dec; 181-182():555-63. PubMed ID: 12505366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multivariate insight into the in vitro antitumour screen database of the National Cancer Institute: classification of compounds, similarities among cell lines and the influence of molecular targets.
    Musumarra G; Condorelli DF; Costa AS; Fichera M
    J Comput Aided Mol Des; 2001 Mar; 15(3):219-34. PubMed ID: 11289076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.